Earnings Per Share
Shares (Diluted)
Vertex Pharmaceuticals Shares (Diluted) decreased by 0.5% to 257.6M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.3%, from 261M to 257.6M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionEarnings Per Share
CategoryCapital Allocation
SignalLower is better
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
An increase relative to basic shares indicates a higher reliance on equity-based compensation or convertible debt financing.
Detailed definition
Weighted-average shares outstanding (diluted) includes the total number of basic common shares plus all additional share...
Peer comparison
Commonly compared against basic shares to determine the 'dilution overhang' present in a company's capital structure.
Metric ID:
is_weighted_shares_dilutedHistorical Data
14 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 261M | 259.7M | 257.9M | 258.7M | 259.5M | 260.3M | 260.4M | 260.6M | 261.1M | 258.1M | 261M | 259.5M | 258.9M | 257.6M |
| QoQ Change | — | -0.5% | -0.7% | +0.3% | +0.3% | +0.3% | +0.0% | +0.1% | +0.2% | -1.1% | +1.1% | -0.6% | -0.2% | -0.5% |
| YoY Change | — | — | — | -0.9% | -0.1% | +0.9% | +0.7% | +0.4% | +0.3% | -0.9% | +0.2% | -0.6% | +0.3% | -1.3% |
Range257.6M – 261.1M
CAGR-0.4%
Avg YoY Growth-0.1%
Median YoY Growth+0.2%
Current Streak3 quarters decline
Shares (Diluted) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's shares (diluted)?
- Vertex Pharmaceuticals (VRTX) reported shares (diluted) of 257.6M in Q3 2025.
- How has Vertex Pharmaceuticals's shares (diluted) changed year-over-year?
- Vertex Pharmaceuticals's shares (diluted) decreased by 1.3% year-over-year, from 261M to 257.6M.
- What does shares (diluted) mean?
- The total number of shares that would exist if all 'potential' shares, like employee stock options, were converted into real stock.